Skip to main content
SpringerLink
Log in

Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

In an attempt to understand the nature of the interactions between D1 and D2 dopamine subsystems as well as between dopamine and acetylcholine, catalepsy was assessed in rats following various drug treatments. The D1-specific antagonist SCH23390 (0.1 mg/kg) produced prompt, potent and brief (<90 min) catalepsy with an ED50 of 0.105 mg (0.3 μmol)/kg. Conversely, fluphenazine (0.1 mg/kg), spiroperidol (0.1 mg/kg), and haloperidol (0.2 mg/kg) all had comparably potent but more slowly rising and prolonged (>240 min) effects. The action of SCH23390 was synergistic with spiroperidol, inhibited by apomorphine or atropine, unaffected by mecamylamine, and markedly potentiated by pilocarpine. However, pilocarpine was unable to significantly potentiate the action of fluphenazine or spiroperidol. It is inferred that SCH23390 differs from the classical neuroleptics in its mechanism of cataleptogenicity, that there is a cholinergic link with the D1 dopamine system, and further, that there may be a difference in the nature or impact of the cholinergic interaction with the D1 and D2 dopamine systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Borison RL, Diamond BI (1980) Anticholinergics promote neuroleptic-induced tardive dyskinesia. Adv Biochem Psychopharmacol 24:359–361

    Google Scholar 

  • Brown JH, Brown SL (1984) Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism. J Biol Chem 259:3777–3781

    Google Scholar 

  • Carey RJ, De Veaugh-Geiss J (1982) Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination. Psychopharmacology 76:341–345

    Google Scholar 

  • Chang WH, Chen TY, Yeh EK (1987) Time-response curves of homovanillic acid in caudate and prefrontal cortex following acute neuroleptic administration. Psychopharmacology 93:403–404

    Google Scholar 

  • Christensen AV, Nielsen IM (1979) Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacology 62:111–116

    Google Scholar 

  • Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D1 antagonist SCH23390 in comparison with neuroleptics. Life Sci 34:1529–1540

    Google Scholar 

  • Clark D, White FJ (1987) Review: D1 dopamine receptor — the search for a function: a critical evaluation of D1/D2 dopamine receptor classification and its functional implications. Synapse 1:347–388

    Google Scholar 

  • Consolo S, Wu CF, Fusi R (1987) D-1 receptor-linked mechanism modulates cholinergic neurotransmission in rat striatum. J Pharmacol Exp Ther 242:300–305

    Google Scholar 

  • Costall B, Hui S-CG, Naylor RJ (1978) Correlation between multi-test and single test catalepsy assessment. Neuropharmacology 17:761–764

    Google Scholar 

  • Creese I (1983) Receptor interactions of neuroleptics. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 194–196

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science 192:481–483

    Google Scholar 

  • Ezrin-Waters C, Seeman P (1977) Tolerance to haloperidol catalepsy. Eur J Pharmacol 41:321–327

    Google Scholar 

  • Ezrin-Waters C, Muller P, Seeman P (1976) Catalepsy induced by morphine or haloperidol: effects of apomorphine and anti-cholinergic drugs. Can J Physiol Pharmacol 54:516–519

    Google Scholar 

  • Fisher SK, Klinger PD, Agranoff BW (1983) Muscarinic agonist binding and phospholipid turnover in brain. J Biol Chem 258:7358–7363

    Google Scholar 

  • Gero A (1971) Intimate study of drug action III: mechanism of molecular drug action. In: DiPalma JR (ed) Drill's pharmacology in medicine. McGraw-Hill, New York, pp 67–98

    Google Scholar 

  • Hess EJ, Albers LJ, Hoang L, Creese I (1986) Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238:846–854

    Google Scholar 

  • Hillegaart V, Ahlenius S, Magnusson O, Fowler CJ (1987) Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacol Biochem Behav 27:159–164

    Google Scholar 

  • Hyttel J (1983) SCH23390: the first selective dopamine D1 antagonist. Eur J Pharmacol 91:153–154

    Google Scholar 

  • Hyttel J (1984) Functional evidence for selective dopamine D1 receptor blockade by SCH23390. Neuropharmacology 23:1395–1401

    Google Scholar 

  • Hyttel J, Larsen JJ, Christensen AV, Arnt J (1985) Receptor binding properties of neuroleptics. In: Casey DE, Chases TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer, New York Berlin Heidelberg Tokyo pp 2–8

    Google Scholar 

  • Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH23390, a potential benzazepine antipsychotic with unique interactions of dopaminergic systems. J Pharmacol Exp Ther 226:462–468

    Google Scholar 

  • Klemm WR, Block H (1988) D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacol Biochem Behav 29:223–229

    Google Scholar 

  • Ladinsky H, Consolo S, Bianchi S, Ghezzi D, Samanin R (1978) Link between dopaminergic and cholinergic neurons in the striatum as evidenced by pharmacological and lesion studies. In: Garattini S, Pujol JF, Samanin R (eds) Interactions between putative neurotransmitters in the brain. Raven Press, New York, pp 3–21

    Google Scholar 

  • Lloyd KG, Stadler H, Bartholini G (1973) Dopamine and acetyl-choline neurones in limbic structures: effect of neuroleptic drugs. In: Usdin E, Snyder S (eds) Frontiers in catechlamine research. Pergamon Press, New York, pp 777–779

    Google Scholar 

  • Mailman RB, Shulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984) SCH23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur J Pharmacol 101:159–160

    Google Scholar 

  • Meller E, Bohmaker K, Goldstein M, Friedhoff AJ (1985a) Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther 233:656–662

    Google Scholar 

  • Meller E, Kuga F, Friedhoff AJ, Goldstein M (1985b) Selective D2 dopamine agonists prevent catalepsy induced by SCH23390, a selective D1 antagonist. Life Sci 36:1857–1864

    Google Scholar 

  • Morelli M, Chiara GD (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117:179–185

    Google Scholar 

  • Munkvad I, Pakkenberg H, Randrup A (1968) Aminergic systems in basal ganglia associated with stereotyped hyperactive behaviour and catalepsy. Brain Behav Evol 1:89–100

    Google Scholar 

  • Olianas MC, Onali P, Neff NH, Costa E (1983) Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum. J Neurochem 41:1364–1369

    Google Scholar 

  • Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet II:223–226

    Google Scholar 

  • Saller CF, Salama AI (1986) D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo. J Pharmacol Exp Ther 236:714–720

    Google Scholar 

  • Seeman P (1981) Brain dopamine receptors. Pharmacol Rev 32:229–313

    Google Scholar 

  • Seeman P (1985) Brain dopamine receptors in schizophrenia and tardive dyskinesia. In: Casey DE, Chases TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer, New York Berlin Heidelberg Tokyo, pp 2–8

    Google Scholar 

  • Shulz DW, Staples L, Mailman RB (1985) SCH23390 causes persistent antidopaminergic effects in vivo: evidence for long term occupation of receptors. Life Sci 36:1941–1948

    Google Scholar 

  • de Sousa Moreira LF, da Concaicao Camargo Pinheiro M, Masur J (1982) Catatonic behavior induced by haloperidol, increased by retesting and elicited without drugs in rats. Pharmacology 25:1–5

    Google Scholar 

  • Stanley ME, Glick SD (1976) Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15:393–394

    Google Scholar 

  • Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors for efflux of cyclic AMP from rat neostriatum. Nature 294:366–368

    Google Scholar 

  • Stoof JC, Kebabian JW (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 35:2281–2296

    Google Scholar 

  • Waddington JL (1986) Behavioral correlates of the action of selective D-1 dopamine receptor antagonists: impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem Pharmacol 35:3661–3667

    Google Scholar 

  • Wilk S, Watson E, Stanley M (1975) Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and clozapine. J Pharmacol Exp Ther 195:265–270

    Google Scholar 

  • Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York, pp 10–428

    Google Scholar 

  • Zetler G (1968) Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int J Neuropharmacol 7:325–335

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Psychiatry and Pharmacology, The Medical College of Pennsylvania at Eastern Pennsylvania Psychiatric Institute, 3200 Henry Avenue, 19129, Philadelphia, PA, USA

    Ashiwel S. Undie & Eitan Friedman

Authors
  1. Ashiwel S. Undie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eitan Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Undie, A.S., Friedman, E. Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics. Psychopharmacology 96, 311–316 (1988). https://doi.org/10.1007/BF00216056

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216056

Key words

Search

Navigation